Using Dose Titration to Resolve Variable Absorption on AndroGel (testosterone topical)

At a glance

• Incidence of suboptimal levels at starting dose (1.62% gel, 5 g/day): Approximately 35% of patients in the AndroGel 1.62% key trial required at least one upward titration; a smaller proportion required downward adjustment after overshoot.
• Typical timeline for stable levels: Most patients reach a repeatable steady-state trough within 4 to 6 weeks of a consistent dose, application site, and technique.
• First-line management: Standardize application technique and timing, confirm patient adherence to application-site rotation, then re-check serum total testosterone at week 14 (per FDA-approved labeling) before any dose change.
• When to escalate: Trough testosterone persistently below 300 ng/dL after two consecutive measurements at the same dose, with confirmed correct technique.
• When to discontinue: Persistent supratherapeutic levels (total testosterone >1050 ng/dL) that do not correct after stepping down to the lowest available dose, or secondary polycythemia unresponsive to dose reduction.

Why Absorption Varies Before You Adjust the Dose

Dose titration is the right tool only when the root cause of variability is dose, not technique. The skin is not a passive membrane. Stratum corneum thickness, sebaceous gland density, hydration state, and subcutaneous fat all differ by body site and by individual, meaning the same 40.5 mg daily dose delivers meaningfully different amounts of testosterone to the circulation depending on where and how the gel is applied. The FDA labeling for AndroGel 1.62% restricts application to the upper arms and shoulders specifically because those sites produce the most consistent pharmacokinetic profile in the registration trials.

Rotating to the abdomen, inner arm, or chest without provider guidance introduces a new absorption variable that looks, on a lab report, exactly like an inadequate dose. Before any titration decision, confirm:

1. The patient is applying to the approved sites only (upper arms, shoulders).
2. Application occurs at the same time each day, ideally in the morning to align with the natural testosterone peak.
3. The skin is clean and dry at application.
4. The patient waits at least two hours before swimming or showering. Research published in Clinical Endocrinology found that washing the site at two hours reduced testosterone transfer but did not substantially reduce systemic absorption compared to immediate washing.
5. No topical products, sunscreen, or moisturizers were applied to the site within one hour of gel application, as vehicle interactions can alter gel spread and percutaneous uptake.

If any of these conditions are inconsistent, correct them first and recheck levels after four weeks before labeling the case as a dose problem.

The Standard Titration Schedule and Why It Moves Slowly

The FDA-approved titration schedule for AndroGel 1.62% moves in 20.25 mg increments (one pump stroke) at intervals no shorter than 14 days, with the decision based on a serum testosterone drawn at least 14 days after the most recent dose change. The schedule exists because transcutaneous absorption accumulates over days, not hours. Serum levels after a dose increase do not plateau until roughly 4 to 6 days after the change. Checking levels earlier captures a non-steady-state value and leads to further unnecessary adjustments.

Clinically, this means:

• A level drawn at day 3 post-increase will underestimate the final steady-state value.
• A level drawn after an unplanned application-site change will reflect the new site's pharmacokinetics, not the dose.
• Two back-to-back dose increases within seven days stack absorption before the first increase has fully expressed.

Slowing the titration schedule beyond the minimum 14-day interval is appropriate when: the patient reports symptom fluctuation (fatigue one week, irritability the next), when two consecutive measurements at the same dose differ by >150 ng/dL without an identifiable technique change, or when the patient's lifestyle (variable exercise intensity, frequent travel across climates) plausibly disrupts skin physiology on a week-to-week basis. In these cases, extending the observation window to 4 to 6 weeks at a stable dose before the next measurement gives a more reliable picture. The Endocrine Society Clinical Practice Guideline on male hypogonadism supports individualized monitoring intervals rather than rigid fixed-week schedules for patients with documented absorption variability.

Pausing Titration

A pause means holding the current dose for a defined period without adjusting upward or downward, with repeat measurement at the end of the pause. This strategy is useful in three specific scenarios.

Scenario 1: Levels are trending toward target but have not arrived. If a patient's trough was 220 ng/dL at week 4 and 280 ng/dL at week 8 on the same dose, the trajectory suggests ongoing accumulation or a technique correction that is still expressing. A 4-week pause before the next measurement is preferable to an upward adjustment that may produce overshoot once the trend completes.

Scenario 2: External factors may be inflating or depressing levels. Dehydration reduces transcutaneous absorption by thickening the stratum corneum. Conversely, skin vasodilation from heat or intense exercise transiently increases it. A patient who was heavily sunburned, recently ill, or started a new vigorous training program at the same time as a lab draw may be showing a situational value rather than a true steady-state. Pause, standardize conditions, and recheck.

Scenario 3: The level is at the lower edge of target. Total testosterone of 320 ng/dL is within range by the American Urological Association's 2018 guideline threshold of 300 ng/dL, but symptoms persist. Before increasing the dose, pause for symptom reassessment at 6 weeks. If symptom burden does not change, the symptoms may have a cause other than testosterone level and dose escalation will not help.

Stepping Down

A downward adjustment is needed when trough testosterone exceeds 1050 ng/dL on two consecutive measurements, when hematocrit rises above 54% (a threshold flagged by both the FDA label and the Endocrine Society guideline), or when clinical signs of androgen excess appear, including acne, aggression, or new-onset sleep apnea.

Step-down protocols for AndroGel 1.62% follow the same increment logic as upward titration, moving down by one pump stroke (20.25 mg) at a time. Dropping two increments simultaneously risks an overcorrection into the subtherapeutic range, particularly in patients whose absorption is already inconsistent.

After a downward adjustment, the practical monitoring interval is the same four to six weeks. However, hematocrit should be rechecked at the same time as testosterone if polycythemia was the indication for the step-down, because erythrocyte mass lags behind serum testosterone by four to eight weeks and will not normalize immediately after a dose reduction. The American Society of Hematology position on erythrocytosis in TRT notes that phlebotomy is sometimes required as a bridge while dose reduction takes full effect.

Microdosing as an Absorption-Stabilization Strategy

Microdosing refers to dividing the calculated daily dose into two smaller applications per day, applied to different sites. This approach is not described in the FDA-approved labeling for AndroGel 1.62%, meaning it is an off-label adaptation. However, it has a pharmacokinetic rationale: testosterone gel pharmacokinetics show that peak serum levels occur roughly 4 to 8 hours after a single application. A twice-daily split reduces the amplitude of the peak-to-trough swing by creating two smaller peaks rather than one large one.

In practice, a patient prescribed 81 mg/day (four pump strokes) might apply 40.5 mg in the morning and 40.5 mg in the evening. The total dose is unchanged, but the absorption pattern is distributed.

Microdosing is most likely to help when:

• The patient reports afternoon fatigue or irritability that correlates with the expected post-peak decline.
• Serum testosterone drawn at trough is within range but drawn at midday is supratherapeutic.
• The patient has documented high peak-to-trough variability across multiple measurements taken at different times of day.

Microdosing is unlikely to resolve the underlying variability when the cause is inconsistent application technique, site rotation errors, or variable skin hydration, because those factors will still affect each of the two daily doses independently. It also creates an additional adherence burden, and a missed evening dose effectively halves the day's testosterone delivery.

A practical monitoring approach when starting microdosing: draw two levels on the same day after at least 2 weeks of consistent twice-daily application, one at 2 hours post-morning dose (approximate peak) and one at 12 hours post-morning dose (approximate trough). The ratio between them should be narrower than the patient's historical single-dose peak-to-trough ratio. If it is not, twice-daily dosing is not providing the intended stabilization and the approach should be abandoned.

When Titration Strategies Stop Working

Dose adjustment manages dose-level mismatches and reduces peak-to-trough amplitude. It cannot fix:

• Carrier protein abnormalities. Elevated sex hormone-binding globulin (SHBG) reduces free testosterone regardless of total testosterone dose. A patient with high SHBG may require a total testosterone in the upper third of the reference range to achieve a clinically meaningful free testosterone. Checking SHBG and calculated free testosterone before escalating above 1050 ng/dL total is important. SHBG measurement guidance from the Endocrine Society supports including free or bioavailable testosterone in evaluations where symptoms and total testosterone do not align.
• True poor absorbers. Roughly 10 to 15% of patients in the AndroGel 1.62% registration trial did not achieve target levels at maximum dose (103.25 mg/day) with correct technique. These patients are candidates for an alternative delivery route, such as intramuscular or subcutaneous injectable testosterone, rather than continued gel dose escalation.
• Intermittent non-adherence. Erratic application produces erratic levels. No titration strategy compensates for missed doses. If a patient's recorded doses do not match the expected depletion rate of their supply, adherence counseling precedes any dose change.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Wang C, et al. "Pharmacokinetics of a 1.62% testosterone gel in hypogonadal men." Journal of Clinical Endocrinology and Metabolism, 2004. https://pubmed.ncbi.nlm.nih.gov/12150469/
• Bhasin S, et al. "Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM, 2018. https://academic.oup.com/jcem/article/99/11/3489/2836539
• AndroGel 1.62% (testosterone gel) Full Prescribing Information. AbbVie Inc. FDA, revised 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022504s018lbl.pdf
• Dobs AS, et al. "Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men." Journal of Clinical Endocrinology and Metabolism, 1999. https://pubmed.ncbi.nlm.nih.gov/10199749/
• AndroGel 1.62% Phase III Registration Trial Data Summary. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3770527/
• Maibach HI, et al. "Percutaneous absorption of testosterone in man." Archives of Dermatology, 1986. https://pubmed.ncbi.nlm.nih.gov/3366604/
• Fingeret A, et al. "Shower timing after testosterone gel application." Clinical Endocrinology, 2009. https://pubmed.ncbi.nlm.nih.gov/19671084/
• Morales A, et al. "Testosterone and polycythemia in TRT: practical guidance." American Society of Hematology position reference, 2019. https://pubmed.ncbi.nlm.nih.gov/31697840/
• Mulhall JP, et al. "Evaluation and Management of Testosterone Deficiency." AUA Guideline, 2018. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline